Kindolor is under clinical development by Lohocla Research and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Kindolor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Kindolor overview

Lohocla-201 (Kindolor) is under development for the treatment of chronic pain and diabetic neuropathic pain. The drug candidate is a new molecular entity (NME) and is administered orally. It targets NMDA receptor, Nav 1.7 and Nav 1.8 sodium channels, delta opioid receptor.

Lohocla Research overview

Lohocla Research is a healthcare services provider that conducts research and development services. Its pipeline products include Kindolor and Nezavist. Kindolor focusses in the development of novel pharmaceuticals for treatment of pain in general, but particularly in the case of treatments for chronic pain. Nezavist is for the treatment of inflammation caused in the gut and the brain by the chronic consumption of alcohol. The company conducts research on alcoholism, neuropathic pain due to diabetes, cancer chemotherapy, proteomic markers of alcohol abuse and depression. It has its operations across the US. Lohocla Research is headquartered in Aurora, Colorado, the US.

For a complete picture of Kindolor’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.